Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced its 2025 first extraordinary general meeting to discuss and approve several key resolutions. These include the adoption of the 2025 A Share Option Scheme and the 2025 H Share RSU Scheme, as well as the renewal of financial and mutual supply agreements with Fosun Finance and Sinopharm. The resolutions aim to enhance the company’s financial management and operational efficiency, potentially impacting its strategic positioning and stakeholder relationships.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. It focuses on the development, manufacture, and distribution of pharmaceutical products and healthcare services, with a market focus on both domestic and international sectors.
YTD Price Performance: 77.63%
Average Trading Volume: 11,635,533
Technical Sentiment Signal: Buy
Current Market Cap: HK$81.13B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.